Pendahuluan Semakin tahun semakin besar kebutuhan akan tanah, baik untuk kepentingan pembangunan perumahan atau gedung maupun untuk pelaksanaan usaha, termasuk usaha pertanian, sedangkan tanah 1 Xxxxx Xxxxxx,XX.XX. adalah Xxxxx Xxxxx III Fakultas Hukum Universitas Batanghari Jambi xxx Xxxxx Tetap PS. Ilmu Hukum Fakultas Hukum Universitas Batanghari Jambi. kosong yang tersedia sudah semakin sedikit xxx tidak pula memiliki tanah sendiri. Dikarenakan tanah sendiri tidak ada atau sangat kecil sedangkan kebutuhan untuk usaha sangat besar, maka diperlukan pihak xxxx xxxx memiliki lahan tanah yang luas untuk menggunakan tanahnya. Pihak yang membutuhkan lahan tanah yang luas untuk usahanya tidak hanya orang perorangan melainkan juga suatu badan usaha. Salah satu badan usaha yang memerlukan lahan tanah yang cukup luas untuk usahanya di kabupaten Muaro Jambi adalah PT. Era Sakti Wiraforestama. Perusahaan ini membutuhkan lahan tanah yang luas guna usaha perkebunan kelapa sawit. Dari usaha yang dilakukan, akhirnya PT. Era Sakti Wiraforestama mendapatkan lahan tanah yang diinginkannya dengan menggunakan tanah xxxxx masyarakat kecamatan Xxxx Xxxx. Penggunaan tanah masyarakat adat Xxxx Xxxx untuk keperluan usaha perkebunan PT. Era Sakti Wiraforestama bukanlah terjadi dengan sendirinya xxx penguasaan semena-mena, melainkan diawali dengan suatu perjanjian kepada xxxxx masyarakat pemilik tanah tersebut. Perjanjian yang diadakan antara PT. Era Sakti Wiraforestama dengan masyarakat adat Xxxx Xxxx adalah perjanjian penggunaan tanah untuk keperluan usaha, yang dituangkan dalam surat perjanjian. Dalam perjanjian yang diadakan, ditentukan xxx xxx kewajiban masing-masing pihak, umumnya hak dari pihak PT. Era Sakti Wiraforestama dapat menggunakan tanah milik masyrakat adat untuk kegiatan usaha perkebunannya hingga jangka waktu yang ditentukan dengan kewajiban membayar sejumlah harga dari hasil perkebunan yang dilakukan xxx mengembalikan pengelolaan tanah tersebut kepada xxxxx masyarakat adat pada saat berakhirnya jangka waktu perjanjian. Sedangkan hak masyarakat adat selaku pemilik tanah selain mendapatkan bagian hasil perkebunan juga mendapatkan tanahnya kembali setelah berakhirnya perjanjian. Dikarenakan penggunaan tanah untuk usaha perkebunan memakan waktu yang cukup lama, maka banyak terjadi perubahan- perubahan dalam pelaksanaan perjanjian yang kadangkala tidak diketahui oleh pihak xxxxx masyarakat, sehingga merugikan xxxxx masyarakat itu sendiri. Dengan terjadinya perubahan-perubahan dalam pelaksanaan perjanjian tanpa diketahui oleh pihak xxxxx masyarakat adat Xxxx Xxxx, timbulah berbagai permasalahan berupa :
SMT XXXXXXXXX XXX, (PAN: XXXXX0000X), wife of Xxx Xxxxxx Xxx, by Nationality Indian, by faith Hindu, by occupation Housewife, residing at Village- Akrampur, PIN-743263, P.O. Akrampur, P.S. Habra, District North 24 Parganas, State West Bengal and (6) SRI XXXXXX XXX, (PAN-XXXXX0000X), son of Xxx Xxxxx Xxxxxx Dey, by Nationality Indian, by faith Hindu, by occupation Service, residing at Village- Akrampur, PIN – 743263, P.O. Akrampur, P.S. Habra, District North 24 Parganas, State West Bengal, hereinafter called and referred to as the VENDORS, all being represented by their Constituted Attorney, XXX XXXXX XXXXXX, (PAN: XXXXX0000X), son of Xxx Xxxxx Xxxxxx, by nationality Indian, by faith Hindu, by occupation Business, residing at BE-111, Sector-I, Salt Lake, Kolkata-700064, Post Office AE Market (Salt Lake City), Police Station Bidhannagar (North), District North 24 Parganas, and being one of the Directors of MAGNOLIA INFRASTRUCTURE DEVELOPMENT LIMITED, (CIN: U70200WB2010PLC152199), (PAN-XXXXX0000X), a Company incorporated under the provisions of the Companies Act, 1956 and having its registered office at 00, Xx. Xxxxxx Xxxxxxx Banerjee Road, Kolkata-700010, Post Office Beliaghata, Police Station: Beliaghata, District South 24 Parganas vide (1) Development Power of Attorney after registration of Development Agreement dated 12th September 2015 registered in the Office of the Additional District Sub-Registrar, Kadambagachi, North 24 Parganas and recorded in Book-I, Volume No. 1519-2015, at Pages 18496 to 18541, being No. 151901639 for the year 2015 and (2) Development Power of Attorney after registration of Development Agreement dated 19th November 2018 registered in the Office of the Additional District Sub-Registrar, Kadambagachi, North 24 Parganas and recorded in Book-I, Volume No. 1519-2015, at Pages 80220 to 80243, being No. 151903193 for the year 2018 (which expression shall unless excluded by or repugnant to the subject or context be deemed to mean and include their respective successors – interest and/or assigns) of the ONE PART. AND MAGNOLIA INFRASTRUCTURE DEVELOPMENT LIMITED, (CIN: U70200WB2010PLC152199), (PAN-XXXXX0000X), a Company incorporated under the provisions of the Companies Act, 1956 and having its registered office at 00, Xx. Xxxxxx Xxxxxxx Banerjee Road, Kolkata -700010, Post Office Beliaghata, Police Station: Beliaghata, District South 24 Parganas, being represented by its Director, XXX XXXXX XXXXXX, (PAN: XXXXX0000X), (AADHAAR NO: 000000000000), son of Xxx Xxxxx Xxxxxx, by nationality Indian, by faith Hindu, by occupation Business, residing at XX-000, Xxxxxx-X, Xxxx Xxxx, Xxxxxxx- 000000, Post Office AE Market (Salt Lake City), Police Station Bidhannagar (North), District North 24 Parganas, hereinafter called and referred to as the “DEVELOPER” (which expression shall unless repugnant to the context or meaning thereof shall include its successors-in-interest and/or permitted assigns of the SECOND PART. AND
Prosthodontics We Cover prosthodontic services as follows: • Removable complete or partial dentures, for Members 15 years of age and above, including six (6) months follow-up care; • Additional services including insertion of identification slips, repairs, relines and rebases and treatment of cleft palate; and • Interim prosthesis for Members five (5) to 15 years of age. We do not Cover implants or implant related services. Fixed bridges are not Covered unless they are required: • For replacement of a single upper anterior (central/lateral incisor or cuspid) in a patient with an otherwise full complement of natural, functional and/or restored teeth; • For cleft palate stabilization; or • Due to the presence of any neurologic or physiologic condition that would preclude the placement of a removable prosthesis, as demonstrated by medical documentation.
Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.
Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.
Gouvernement des États-Unis Le logiciel et la documentation constituent des « Commercial Items » (éléments commerciaux), tel que ce terme est défini dans la clause 48 C.F.R. (Code of Federal Rules) §2.101, consistant en « Commercial Computer Software » (logiciel) et « Commercial Computer Software Documentation » (documentation), tels que ces termes sont utilisés dans les clauses 48 C.F.R. §12.212 ou 48 C.F.R. §227.7202. Conformément à la clause 48 C.F.R. §12.212 ou 48 C.F.R. §227.7202-1 à 227.7202-4, le « Commercial Computer Software » et le « Commercial Computer Software Documentation » sont fournis sous licence au gouvernement des États-Unis (a) uniquement comme « Commercial Items » et (b) uniquement accompagnés des droits octroyés à tous les autres utilisateurs conformément aux termes et conditions ci-inclus. Droits non publiés réservés en vertu de la législation des droits d’auteur en vigueur aux États-Unis.
Exportbepalingen Het is u niet toegestaan de Apple software te gebruiken of anderszins te exporteren of te herexporteren, behalve voor zover toegestaan krachtens de wetten van de Verenigde Staten en van het rechtsgebied waarin u de Apple software hebt verkregen. In het bijzonder, maar zonder beperking, is het u niet toegestaan de Apple software te exporteren of te herexporteren (a) naar een land waarvoor door de Verenigde Staten een embargo is ingesteld of (b) naar enige persoon die voorkomt op de door het U.S. Treasury Department samengestelde lijst van "Specially Designated Nationals" of op de door het U.S. Department of Commerce samengestelde "Denied Person’s List" of "Entity List". Door de Apple software te gebruiken, verklaart u dat u zich niet bevindt in een dergelijk land of op een van de bovengenoemde lijsten voorkomt. U verklaart tevens dat u de Apple software niet zult gebruiken voor doeleinden die verboden zijn volgens de wetten van de Verenigde Staten met inbegrip van, maar niet beperkt tot, de ontwikkeling, het ontwerp, de fabricage of productie van raketten, nucleaire, chemische of biologische wapens.
Vlastnictví Zdravotnické zařízení si ponechá a bude uchovávat Zdravotní záznamy. Zdravotnické zařízení a Zkoušející převedou na Zadavatele veškerá svá práva, nároky a tituly, včetně práv duševního vlastnictví k Důvěrným informacím (ve smyslu níže uvedeném) a k jakýmkoli jiným Studijním datům a údajům.
Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.
Manufacturing License Subject to the terms of this Agreement, including without limitation Section 2.2, Theravance grants to GSK an exclusive license under the Theravance Patents and Theravance Know-How to make and have made API Compound or formulated Alliance Product in the Territory.
